# Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-pyrotinib-in-advanced-lung-adenocarcinoma-with-her2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Zhengbo Song,Yuping Li,Shiqing Chen,Shenpeng Ying,Shuguang Xu,Jianjin Huang,Dan Wu,Dongqing Lv,Ting Bei,Shuxun Liu,Xiaoping Huang,Congying Xie,Xiaoyu Wu,Jianfei Fu,Feng Hua,Wenxian Wang,C. Xu,Chan Gao,Shangli Cai,Shun Lü,Yiping Zhang |
| Citations | 65 |
| DOI | 10.1186/s12916-022-02245-z |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://bmcmedicine.biomedcentral.com/counter/pdf/10.1186/s12916-022-02245-z |
| OpenAlex ID | https://openalex.org/W4210484120 |
| PMID | 35101045 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Wenxian Wang](https://scholariq.org/researchers/wenxian-wang/)
- [C. Xu](https://scholariq.org/researchers/c-xu/)

## Paper journal

- [BMC Medicine](https://scholariq.org/journals/bmc-medicine/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.